Market Trends of Alzheimer's Disease Diagnostics And Therapeutics Industry
Cholinesterase Inhibitors is Expected to Witness a Significant Growth Over the Forecast Period.
Cholinesterase inhibitors, also known as acetylcholinesterase inhibitors, are a class of therapeutics that stop the normal breakdown of acetylcholine, a neurotransmitter. The cholinesterase inhibitors shut off the action of the enzyme cholinesterase, which is responsible for breaking down acetylcholine neurotransmitters in the body. As cholinesterase inhibitors are found to slightly delay the loss of brain function in people suffering from mild to moderate focus Alzheimers disease, they are widely prescribed to treat symptoms related to memory, thinking, language, judgment, and other thought processes. Currently, the major cholinesterase inhibitor drugs available for Alzheimer's use in the market are donepezil, galantamine, rivastigmine, and memantine.
Currently, in the market, cholinesterase inhibitors are the drugs available for Alzheimer's because the enzyme cholinesterase is a significant therapeutic primary for Alzheimer's. Hence, the segment is expected to grow over the forecast period as several pharmaceutical companies Alzheimer's develop Alzheimer's therapeutics based on cholinesterase inhibitors. For instance, in February 2023, Merck Sharp & Dohme LLC conducted a study, Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007), which is in phase I stage.
Also, a recent study published in March 2022, led by Karolinska Institute researchers in Sweden, demonstrated continued cognitive advantages and decreased mortality for up to five years following diagnosis. The findings demonstrated that cholinesterase inhibitor therapy was related to slower cognitive deterioration over five years and 27% decreased mortality in Alzheimer's disease patients compared with controls.
Thus, due to the practical results of cholinesterase inhibitors in treating Alzheimer's disease, new product launches and the increasing geriatric population are expected to witness significant growth over the forecast period.
North America is Expected to Witness a Significant Growth Over the Forecast Period.
North America is expected to witness significant growth over the forecast period owing to the high burden of Alzheimer's disease and the increasing aging population, huge investment in research and development activities, and the launch of new products in the region.
In February 2023, Lantheus Holdings, Inc. acquired Knoxville-based Cerveau Technologies, Inc. Cerveau’s asset is MK-6240, a second-generation F 18-labeled positron emission tomography (“PET”) imaging agent that targets Tau tangles in Alzheimer’s disease. In January 2023, Otsuka and Lundbeck stated that the Food and Drug Administration (FDA) accepted and assigned the application priority review of sNDA for aripiprazole to treat agitation associated with Alzheimer’s dementia. Hence, such company activities and government support are expected to increase the market over the forecast period.
Also, the growing aging population in the region is expected to increase the burden of Alzheimer's disease, as the geriatric population is more prone to neurodegenerative diseases like Alzheimer's as it is an age-associated disease. For instance, in March 2022, the Alzheimer's Association Report stated that approximately 6.2 million people aged 65 years and more are living with Alzheimer 's-related dementia in the United States, and it is projected that this number will increase to 13.8 million people by 2060.
With the increasing number of research studies related to the diagnosis and management of Alzheimer's disease and high investment in the country over Alzheimer's by the government and private entities, the market is expected to grow in the United States over the forecast period. For instance, as per the NIH in May 2022, the funding for research and development of Alzheimer’s Disease in 2021 is estimated to be USD 3,059 million, which rises to USD 3,348 million in 2022
Therefore, due to the high burden of Alzheimer's disease and huge investment in research and development activities, coupled with the launch of new products, the Alzheimer's disease diagnostics and therapeutics market is expected to grow over the forecast period in the region
